
    
      The investigators plan to test the effects of 10-60 mg dronabinol (oral THC) on subjective
      (surveys) and objective (polysomnographically scored (PSG)) sleep in non-frequent and
      frequent cannabis users following an acclimation and baseline night of sleep. The mornings
      after baseline sleep and dronabinol administration, cognitive performance will also be
      measured and participants may also perform morning typical behaviors such as change in
      posture (getting out of bed/tilt test) and mild intensity physical activity. This pilot study
      is in healthy young adults without a history of chronic disease.
    
  